Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
SEATTLE, May 30, 2017 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it will webcast the company’s presentation at the 2017 Jefferies Healthcare Conference in New York City, on Wednesday, June 7, 2017.
The webcast is scheduled to begin at 1:30pm ET and will feature a company overview by Brad Gray, president and chief executive officer of NanoString. Interested parties can access the live webcast with accompanying slides from the investor section of the company’s website at www.nanostring.com. The webcast replay will be available one hour after the conclusion of the live presentation and archived for 90 days.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,600 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
NanoString, NanoString Technologies, the NanoString logo, 3D Biology, nCounter and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
Contact: Doug Farrell Vice President, Investor Relations & Corporate Communications [email protected] Phone: 206-602-1768
